AR064735A1 - Agonistas de gpcr y composicion farmaceutica en base al compuesto - Google Patents

Agonistas de gpcr y composicion farmaceutica en base al compuesto

Info

Publication number
AR064735A1
AR064735A1 ARP080100017A ARP080100017A AR064735A1 AR 064735 A1 AR064735 A1 AR 064735A1 AR P080100017 A ARP080100017 A AR P080100017A AR P080100017 A ARP080100017 A AR P080100017A AR 064735 A1 AR064735 A1 AR 064735A1
Authority
AR
Argentina
Prior art keywords
compound
pharmaceutical composition
composition based
gpcr agonists
alkyl
Prior art date
Application number
ARP080100017A
Other languages
English (en)
Spanish (es)
Original Assignee
Prosidion Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0700125A external-priority patent/GB0700125D0/en
Priority claimed from GB0708746A external-priority patent/GB0708746D0/en
Priority claimed from GB0719763A external-priority patent/GB0719763D0/en
Application filed by Prosidion Ltd filed Critical Prosidion Ltd
Publication of AR064735A1 publication Critical patent/AR064735A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ARP080100017A 2007-01-04 2008-01-03 Agonistas de gpcr y composicion farmaceutica en base al compuesto AR064735A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0700125A GB0700125D0 (en) 2007-01-04 2007-01-04 GPCR agonists
GB0708746A GB0708746D0 (en) 2007-05-08 2007-05-08 GPCR agonists
GB0719763A GB0719763D0 (en) 2007-10-10 2007-10-10 GPCR agonists

Publications (1)

Publication Number Publication Date
AR064735A1 true AR064735A1 (es) 2009-04-22

Family

ID=39199058

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080100017A AR064735A1 (es) 2007-01-04 2008-01-03 Agonistas de gpcr y composicion farmaceutica en base al compuesto

Country Status (20)

Country Link
US (1) US20100105732A1 (enExample)
EP (2) EP2114935B1 (enExample)
JP (1) JP2010514831A (enExample)
AR (1) AR064735A1 (enExample)
AT (1) ATE517103T1 (enExample)
BR (1) BRPI0806500A2 (enExample)
CA (1) CA2674455A1 (enExample)
CL (1) CL2008000018A1 (enExample)
CY (1) CY1112474T1 (enExample)
DK (1) DK2114935T3 (enExample)
EA (1) EA015130B1 (enExample)
HR (1) HRP20110750T1 (enExample)
PE (1) PE20081659A1 (enExample)
PL (1) PL2114935T3 (enExample)
PT (1) PT2114935E (enExample)
RS (1) RS51943B (enExample)
SA (1) SA08280757B1 (enExample)
SI (1) SI2114935T1 (enExample)
TW (1) TW200835482A (enExample)
WO (1) WO2008081207A1 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0516407A (pt) * 2004-12-24 2008-09-02 Prosidion Ltd agonistas de receptor acoplado à proteìna g (gpr116) e uso destes para o tratamento de obesidade e diabetes
MX2007016508A (es) * 2005-06-30 2008-03-04 Prosidion Ltd Agonistas del receptor acoplado a la proteina g.
CL2008000017A1 (es) * 2007-01-04 2008-08-01 Prosidion Ltd Compuestos derivados de heterociclos de nitrogeno y oxigeno, agonistas de gpcr; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la obesidad, diabetes, sindrome metabolico, hiperlipidemia, toleranci
WO2009034388A1 (en) 2007-09-10 2009-03-19 Prosidion Limited Compounds for the treatment of metabolic disorders
CN104016970A (zh) 2007-10-10 2014-09-03 诺华股份有限公司 螺环吡咯烷类与其对抗hcv和hiv感染的应用
GB0812641D0 (en) * 2008-07-10 2008-08-20 Prosidion Ltd Compounds
GB0812649D0 (en) * 2008-07-10 2008-08-20 Prosidion Ltd Compounds
GB0812648D0 (en) * 2008-07-10 2008-08-20 Prosidion Ltd Compounds
WO2010084512A1 (en) * 2008-12-24 2010-07-29 Cadila Healthcare Limited Novel oxime derivatives
GB0904285D0 (en) * 2009-03-12 2009-04-22 Prosidion Ltd Compounds for the treatment of metabolic disorders
GB0904284D0 (en) 2009-03-12 2009-04-22 Prosidion Ltd Compounds for the treatment of metabolic disorders
GB0904287D0 (en) 2009-03-12 2009-04-22 Prosidion Ltd Compounds for the treatment of metabolic disorders
EP2445901A1 (en) 2009-06-24 2012-05-02 Boehringer Ingelheim International GmbH New compounds, pharmaceutical composition and methods relating thereto
US8293729B2 (en) 2009-06-24 2012-10-23 Boehringer Ingelheim International Gmbh Compounds, pharmaceutical composition and methods relating thereto
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
JP2013522279A (ja) 2010-03-18 2013-06-13 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糖尿病及び関連状態の治療で用いるｇｐｒ１１９作動薬とｄｄｐ−ｉｖ阻害薬リナグリプチンの組合せ
GB201006166D0 (en) 2010-04-14 2010-05-26 Prosidion Ltd Compounds for the treatment of metabolic disorders
GB201006167D0 (en) 2010-04-14 2010-05-26 Prosidion Ltd Compounds for the treatment of metabolic disorders
TW201209054A (en) 2010-05-28 2012-03-01 Prosidion Ltd Novel compounds
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
WO2012066077A1 (en) 2010-11-18 2012-05-24 Prosidion Limited 1,4 di substituted pyrrolidine - 3 - yl -amine derivatives and their use for the treatment of metabolic disorders
GB201114389D0 (en) 2011-08-22 2011-10-05 Prosidion Ltd Novel compounds
ES2602813T3 (es) 2011-06-09 2017-02-22 Rhizen Pharmaceuticals S.A. Nuevos compuestos como moduladores de GPR-119
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
CN104610390A (zh) * 2015-02-13 2015-05-13 佛山市赛维斯医药科技有限公司 一种含氨基葡萄糖和腈基吡啶结构的gpr119激动剂及其用途
CN104610393A (zh) * 2015-02-13 2015-05-13 佛山市赛维斯医药科技有限公司 一类含氨基葡萄糖和卤代吡啶结构化合物及其用途

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3576810A (en) * 1968-06-20 1971-04-27 Robins Co Inc A H 1-substituted-3-(-4)-aroylpiperidines
US5252586A (en) * 1990-09-28 1993-10-12 The Du Pont Merck Pharmaceutical Company Ether derivatives of alkyl piperidines and pyrrolidines as antipsychotic agents
FR2692575B1 (fr) 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
FR2713225B1 (fr) 1993-12-02 1996-03-01 Sanofi Sa N-pipéridino-3-pyrazolecarboxamide substitué.
DE4222565A1 (de) * 1992-07-09 1994-01-13 Hoechst Ag Meta-substituierte Sechsringaromaten zur Verwendung in Flüssigkristallmischungen
US6100042A (en) 1993-03-31 2000-08-08 Cadus Pharmaceutical Corporation Yeast cells engineered to produce pheromone system protein surrogates, and uses therefor
DE4311967A1 (de) * 1993-04-10 1994-10-13 Hoechst Ag Smektische Flüssigkristallmischung
DE4311968A1 (de) * 1993-04-10 1994-10-20 Hoechst Ag Smektische Flüssigkristallmischung
US5338738A (en) * 1993-04-19 1994-08-16 Bristol-Myers Squibb Company Cerebral function enhancers: acyclic amide derivatives of pyrimidinylpiperidines
FR2705346B1 (fr) * 1993-05-18 1995-08-11 Union Pharma Scient Appl Nouveaux dérivés de pipéridinyl thio indole, leurs procédés de préparation, compositions pharmaceutiques les contenant, utiles notamment comme antalgiques .
JPH11513382A (ja) * 1995-10-20 1999-11-16 ドクトル カルル トーマエ ゲゼルシャフト ミット ベシュレンクテル ハフツング ５員複素環化合物、これらの化合物を含む医薬品、それらの使用及びそれらの調製方法
WO1998006720A1 (fr) 1996-08-09 1998-02-19 Eisai Co., Ltd. Derives de benzopiperidine
GB9719496D0 (en) 1997-09-13 1997-11-19 Glaxo Group Ltd G protien chimeras
WO2000012704A2 (en) 1998-09-01 2000-03-09 Basf Aktiengesellschaft Enhanced functional expression of g protein-coupled receptors
US6221660B1 (en) * 1999-02-22 2001-04-24 Synaptic Pharmaceutical Corporation DNA encoding SNORF25 receptor
KR100635892B1 (ko) * 2000-11-21 2006-10-18 미쓰비시 가가꾸 가부시키가이샤 2-(4-피리딜)에탄티올의 제조 방법
FR2829027A1 (fr) 2001-08-29 2003-03-07 Aventis Pharma Sa Association avec un antagoniste du recepteur cb1, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement de la maladie de parkinson
FR2829028B1 (fr) 2001-08-29 2004-12-17 Aventis Pharma Sa Association d'un antagoniste du recepteur cb1 et d'un produit qui active la neurotransmission dopaminergique dans le cerveau, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement de la maladie de
EP1421077A4 (en) 2001-08-31 2004-11-17 Univ Connecticut NEW PYRAZOLANALOGS ON CANNABINOID RECEPTORS
TWI231757B (en) 2001-09-21 2005-05-01 Solvay Pharm Bv 1H-Imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity
AU2002333853B2 (en) 2001-09-21 2006-07-13 Solvay Pharmaceuticals B.V. 4,5-dihydro-1H-pyrazole derivatives having potent CB1-antagonistic activity
ES2272809T3 (es) 2001-09-21 2007-05-01 Solvay Pharm Bv Nuevos derivados de 4,5-dihidro-1h-pirazol con actividad antagonista de cb1.
FR2831883B1 (fr) 2001-11-08 2004-07-23 Sanofi Synthelabo Forme polymorphe du rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant
SE0104330D0 (sv) 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
SE0104332D0 (sv) 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
FR2833842B1 (fr) 2001-12-21 2004-02-13 Aventis Pharma Sa Compositions pharmaceutiques a base de derives d'azetidine
AU2003209388A1 (en) 2002-01-29 2003-09-02 Merck And Co., Inc. Substituted imidazoles as cannabinoid receptor modulators
WO2003075660A1 (en) 2002-03-06 2003-09-18 Merck & Co., Inc. Method of treatment or prevention of obesity
WO2003077847A2 (en) 2002-03-12 2003-09-25 Merck & Co., Inc. Substituted amides
AR038966A1 (es) 2002-03-18 2005-02-02 Solvay Pharm Bv Derivados de tiazol que tienen actividad antagonista, agonista o agonista parcial de cb1
EP1490043A4 (en) 2002-03-26 2007-05-30 Merck & Co Inc SPIROCYCLIC AMIDS AS CANNABINOID RECEPTOR MODULATORS
ES2192494B1 (es) 2002-03-27 2005-02-16 Consejo Superior De Investigaciones Cientificas Derivados de 1,2,4-triazol con propiedades cannabinoides.
WO2003082191A2 (en) 2002-03-28 2003-10-09 Merck & Co., Inc. Substituted 2,3-diphenyl pyridines
JP2005527586A (ja) 2002-04-05 2005-09-15 メルク　エンド　カムパニー　インコーポレーテッド 置換アリールアミド
FR2838438A1 (fr) 2002-04-11 2003-10-17 Sanofi Synthelabo Derives de diphenylpyridine,leur preparation, les compositions pharmaceutiques en contenant
FR2838439B1 (fr) 2002-04-11 2005-05-20 Sanofi Synthelabo Derives de terphenyle, leur preparation, les compositions pharmaceutqiues en contenant
US7667053B2 (en) 2002-04-12 2010-02-23 Merck & Co., Inc. Bicyclic amides
US6825209B2 (en) 2002-04-15 2004-11-30 Research Triangle Institute Compounds having unique CB1 receptor binding selectivity and methods for their production and use
CA2493313C (en) 2002-07-29 2010-03-09 F. Hoffmann-La Roche Ag Novel benzodioxoles
WO2004012671A2 (en) 2002-08-02 2004-02-12 Merck & Co., Inc. Substituted furo [2,3-b] pyridine derivatives
US20050101542A1 (en) 2002-08-20 2005-05-12 Regents Of The University Of California Combination therapy for controlling appetites
HRP20050053A2 (en) 2002-09-19 2005-04-30 Solvay Pharmaceuticals B.V. 1 h-1,2,4-triazole-3-carboxamide derivatives as cannabinoid-cb1 receptor ligands
US7405221B2 (en) 2002-09-27 2008-07-29 Merck & Co., Inc. Substituted pyrimidines
EP1556373A1 (en) 2002-10-18 2005-07-27 Pfizer Products Inc. Cannabinoid receptor ligands and uses thereof
US7129239B2 (en) 2002-10-28 2006-10-31 Pfizer Inc. Purine compounds and uses thereof
US7247628B2 (en) 2002-12-12 2007-07-24 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
AU2003300967B2 (en) 2002-12-19 2009-05-28 Merck Sharp & Dohme Corp. Substituted amides
GB0230087D0 (en) 2002-12-24 2003-01-29 Astrazeneca Ab Therapeutic agents
CN100360527C (zh) 2003-01-02 2008-01-09 霍夫曼-拉罗奇有限公司 Cb1受体反激动剂
TW200413328A (en) 2003-01-02 2004-08-01 Hoffmann La Roche Novel CB 1 receptor inverse agonists
US7329658B2 (en) 2003-02-06 2008-02-12 Pfizer Inc Cannabinoid receptor ligands and uses thereof
JP2006517550A (ja) 2003-02-13 2006-07-27 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 置換ヘキサヒドロピラジノ［１，２−ａ］ピリミジン−４，７−ジオン誘導体、その製造方法および医薬としてのその使用
RS20050572A (sr) 2003-02-13 2007-09-21 Sanofi-Aventis Deutschland Gmbh., AZOTOM SUPSTITUISANI HEKSAHIDRO- PIRAZINO(1,2-A)PIRIMIDIN -4,7-DION DERIVATI, POSTUPAK ZA NjIHOVU PROIZVODNjU I NjIHOVA PRIMENA KAO LEKA
US7169797B2 (en) * 2003-02-14 2007-01-30 Abbott Laboratories Protein-tyrosine phosphatase inhibitors and uses thereof
US20040167188A1 (en) * 2003-02-14 2004-08-26 Zhili Xin Protein-tyrosine phosphatase inhibitors and uses thereof
EP1606019A1 (en) 2003-03-07 2005-12-21 The University Court of The University of Aberdeen Cannabinoid receptor inverse agonists and neutral antagonists as therapeutic agents for the treatment of bone disorders
US7232823B2 (en) 2003-06-09 2007-06-19 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
AR045496A1 (es) * 2003-08-29 2005-11-02 Schering Corp Analolgos de benzimidazolpiperidinas 2- substiyuidas como antagonistas de los receptores de la hormona que concentra melanina selectivos para el tratamiento de la obesidad y trastornos relacionados
EP1711491A1 (en) 2003-12-24 2006-10-18 Prosidion Limited Heterocyclic derivatives as gpcr receptor agonists
WO2006067532A1 (en) 2004-12-24 2006-06-29 Prosidion Ltd G-protein coupled receptor agonists
BRPI0516407A (pt) 2004-12-24 2008-09-02 Prosidion Ltd agonistas de receptor acoplado à proteìna g (gpr116) e uso destes para o tratamento de obesidade e diabetes
GB0428514D0 (en) 2004-12-31 2005-02-09 Prosidion Ltd Compounds
DOP2006000008A (es) * 2005-01-10 2006-08-31 Arena Pharm Inc Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
WO2007003961A2 (en) 2005-06-30 2007-01-11 Prosidion Limited Gpcr agonists
MX2007016508A (es) * 2005-06-30 2008-03-04 Prosidion Ltd Agonistas del receptor acoplado a la proteina g.
CA2613236A1 (en) 2005-06-30 2007-01-11 Prosidion Limited G-protein coupled receptor agonists
EP1907383A1 (en) 2005-06-30 2008-04-09 Prosidion Limited Gpcr agonists
WO2007116229A1 (en) * 2006-04-06 2007-10-18 Prosidion Limited Heterocyclic gpcr agonists
ES2374952T3 (es) * 2006-12-06 2012-02-23 Glaxosmithkline Llc Compuestos bicíclicos y uso como antidiabéticos.
CL2008000017A1 (es) * 2007-01-04 2008-08-01 Prosidion Ltd Compuestos derivados de heterociclos de nitrogeno y oxigeno, agonistas de gpcr; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la obesidad, diabetes, sindrome metabolico, hiperlipidemia, toleranci

Also Published As

Publication number Publication date
PE20081659A1 (es) 2008-10-24
EP2114935B1 (en) 2011-07-20
EP2114935A1 (en) 2009-11-11
SI2114935T1 (sl) 2011-11-30
CY1112474T1 (el) 2015-12-09
CA2674455A1 (en) 2008-07-10
WO2008081207A1 (en) 2008-07-10
HK1135705A1 (en) 2010-06-11
JP2010514831A (ja) 2010-05-06
PT2114935E (pt) 2011-10-17
EP2377864A1 (en) 2011-10-19
HRP20110750T1 (hr) 2011-11-30
BRPI0806500A2 (pt) 2014-04-22
RS51943B (sr) 2012-02-29
TW200835482A (en) 2008-09-01
EA200900880A1 (ru) 2010-02-26
EA015130B1 (ru) 2011-06-30
US20100105732A1 (en) 2010-04-29
ATE517103T1 (de) 2011-08-15
CL2008000018A1 (es) 2008-08-01
SA08280757B1 (ar) 2011-01-15
DK2114935T3 (da) 2011-10-31
PL2114935T3 (pl) 2012-03-30

Similar Documents

Publication Publication Date Title
AR064735A1 (es) Agonistas de gpcr y composicion farmaceutica en base al compuesto
AR064736A1 (es) Agonistas de gpcr
ATE523507T1 (de) Piperidin-gpcr-agonisten
ATE557024T1 (de) Piperidinverbindungen als gpcr-agonisten
PE20120218A1 (es) Compuestos para el tratamiento de trastornos metabolicos
AR061644A1 (es) Derivados de benzofurano
TN2009000129A1 (en) Indole compound
PE20120693A1 (es) Compuestos heterociclos como moduladores de la piruvato cinasa m2 (pkm2)
ATE479677T1 (de) Pyrimidinderivate als gpcr-agonisten
TN2012000002A1 (en) Gpr119 agonists
NO20083480L (no) Piperidinoylpyrrolidiner som melanokortin type 4 reseptor agonister
ATE557023T1 (de) Piperidinylverbindungen als gpcr-agonisten
SV2009002865A (es) Uso de oxazolidinonas para el tratamiento y profilaxis de microangiopatias
PE20110329A1 (es) Agonistas del receptor acoplado a la proteina g piperidinilo
PE20091842A1 (es) Pirrolidinonas como activadores de glucoquinasa
AR063028A1 (es) Derivados heterociclicos de piridin-2-carboxamida activadores de glucoquinasas, utiles para el tratamiento de diabetes y obesidad y composiciones farmaceuticas que los contienen.
PE20080768A1 (es) Compuestos de isoindolina 5-sustituidos
AR064521A1 (es) Activador de glucoquinasa
PE20120648A1 (es) Compuestos de 4-isopropilfenilglucitol como inhibidores de sglt1
PE20070498A1 (es) Compuestos derivados de indoles de acilo como antagonistas del receptor de glucagon
AR077094A1 (es) Derivados de pirazinooxazepina, composiciones farmaceuticas y su uso en el tratamiento de un sintoma del aparato urinario inferior, obesidad y/o prolapso de organos
CO6150175A2 (es) Compuesto triciclico y uso farmaceutico del mismo
PE20091890A1 (es) COMPUESTOS DE 3-FENILPIRAZOLO [5,1-b] TIAZOL
AR065724A1 (es) Macrolidos
AR065864A1 (es) Compuesto de oxi-ciclohexil-piperidinil-dihidro-benzimidazol-2-ona composicion farmacetica que lo comprende su uso para la preparacion de un medicamento y compuestos intermediarios para su preparacion

Legal Events

Date Code Title Description
FB Suspension of granting procedure